Capsid-Targeting Approach for HBV, HIV Fetches Novira $23M

Over the past two years, the advent of protease inhibitors launched a paradigm shift that is changing the landscape of hepatitis C treatment. Now, 2009 biotech start-up Novira Therapeutics Inc. is looking to foster a similar revolution in hepatitis B, and its capsid-targeting approach got a boost last week with the closing of a $23 million Series A financing.